Vendor Intelligence Report: Cellupep

Published 3 Jul 2026. 26-page investigative report on who is behind Cellupep: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 27 Finnrick lab tests, Cellupep records 18 pass / 9 fail, an overall pass rate of 67%. The useful signal is not a blanket vendor grade: Retatrutide is the relative strength, GHK-Cu looks strong but is complicated by a historical severe overfill event, and BPC-157 plus TB-500 are the weak end of the tested catalog. Under stricter grading, the dispersion matters more than the headline.

The investigation finds a young, thinly identified operation behind a manufacturer-style pitch. Current public assets trace mainly to 2025–2026 domains, privacy-protected registration, WhatsApp/Gmail support, and a personal lead around Kun; no verifiable legal entity surfaced in the searched registries. The homepage’s 9 years experience and USA warehouse claims sit uneasily beside a Telegram-origin shipping description and the absence of a disclosed warehouse address.

Cellupep’s document trail is a separate buyer problem. The COA gallery includes some CelluPep-named Janoshik reports, but also lab certificates issued to unrelated clients, meaning screenshots cannot be treated as lot proof. Fulfillment evidence is similarly uneven: Reddit records include deliveries and positive effects, but also dead tracking, customs explanations, and support dropoff, while the new European storefront adds UK WhatsApp and Instagram channels without an EU legal counterparty.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all 4 tested products
  • Domain chronology for cellupep.com, cellupeptide.com, and cellupep.org, including the unreachable secondary domain
  • Corporate-registry, trademark, import-record, and operator-identifier checks around Cellupep and Kun
  • COA provenance review covering CelluPep Janoshik reports and unrelated-client MZ Biolabs/Vanguard certificates
  • Fulfillment, customs, Reddit-sentiment, and buyer-recourse assessment for China-origin peptide orders
  • Promotion scan results across X, web coupon pages, referral-code searches, and unswept Instagram/Telegram leads

Risk assessment

  • Product-specific dosing-control risk — high: BPC-157 (40.31%) and TB-500 (39.41%) show poor reliability; GHK-Cu (86.33%) requires exact-lot caution due to a historical +227% overfill; Retatrutide (82.08%) is the comparatively stronger Cellupep option.
  • COA provenance and exact-lot verification risk — high: Gallery COAs mix CelluPep Janoshik reports with MZ Biolabs reports to Edward Jacobs and a Vanguard report to Regenerative Health Peptides; screenshot COAs are not lot proof.
  • Fulfillment failure risk — high: Reddit reports describe dead tracking, customs explanations, and support silence; some orders appear to arrive, but reliability and replacement recourse are uneven.
  • Corporate accountability, channel-verification and recourse risk — medium: No verifiable legal entity surfaced; domains are privacy-protected or unstable, contacts run through WhatsApp/Gmail, and Cellupep publishes no clean official-channel or authorized-reseller list.
  • Misleading history and warehouse-claim risk — medium: The 9+ years and USA warehouse claims are unsupported by 2025–2026 domain records, absent US warehouse disclosure, and the Telegram description stating China-origin shipping.
  • Customs seizure risk for Retatrutide and Semax — medium: CBP’s 2026 seizure notice named Retatrutide and Semax in mis-manifested China-origin peptide shipments; not proven Cellupep-specific, but product and channel overlap raises loss risk.